6:05 PM
 | 
May 27, 2016
 |  BC Extra  |  Company News

EC approves GSK's Strimvelis

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said the European Commission approved gene therapy Strimvelis ( GSK2696273) to treat patients with severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID) for whom no suitable HLA-matched related...

Read the full 164 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >